London · Delayed Price · Currency is GBP · Price in USD Alnylam Pharmaceuticals Statistics
Total Valuation
LON:0HD2 has a market cap or net worth of GBP 39.76 billion. The enterprise value is 39.67 billion.
| Market Cap | 39.76B |
| Enterprise Value | 39.67B |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 131.08M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.49% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 125.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.13 |
| PB Ratio | 217.38 |
| P/TBV Ratio | 217.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -170.34 |
| EV / Sales | 21.34 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.80, with a Debt / Equity ratio of 10.93.
| Current Ratio | 2.80 |
| Quick Ratio | 2.63 |
| Debt / Equity | 10.93 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.18 |
Financial Efficiency
Return on equity (ROE) is -257.82% and return on invested capital (ROIC) is -3.95%.
| Return on Equity (ROE) | -257.82% |
| Return on Assets (ROA) | -2.63% |
| Return on Invested Capital (ROIC) | -3.95% |
| Return on Capital Employed (ROCE) | -5.52% |
| Revenue Per Employee | 805,824 |
| Profits Per Employee | -104,441 |
| Employee Count | 2,230 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 5.32 |
Taxes
| Income Tax | -44.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +68.17% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +68.17% |
| 50-Day Moving Average | 313.88 |
| 200-Day Moving Average | 272.34 |
| Relative Strength Index (RSI) | 82.46 |
| Average Volume (20 Days) | 120 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LON:0HD2 had revenue of GBP 1.80 billion and -232.90 million in losses. Loss per share was -1.80.
| Revenue | 1.80B |
| Gross Profit | 1.50B |
| Operating Income | -131.52M |
| Pretax Income | -277.05M |
| Net Income | -232.90M |
| EBITDA | -89.94M |
| EBIT | -131.52M |
| Loss Per Share | -1.80 |
Balance Sheet
The company has 2.09 billion in cash and 2.00 billion in debt, giving a net cash position of 86.02 million.
| Cash & Cash Equivalents | 2.09B |
| Total Debt | 2.00B |
| Net Cash | 86.02M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 182.91M |
| Book Value Per Share | 1.40 |
| Working Capital | 1.71B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 83.20%, with operating and profit margins of -7.32% and -12.96%.
| Gross Margin | 83.20% |
| Operating Margin | -7.32% |
| Pretax Margin | -15.42% |
| Profit Margin | -12.96% |
| EBITDA Margin | -5.01% |
| EBIT Margin | -7.32% |
| FCF Margin | n/a |
Dividends & Yields
LON:0HD2 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.49% |
| Shareholder Yield | n/a |
| Earnings Yield | -0.59% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |